RecruitingPhase 2NCT02106988

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Patients With Stage I/II Nasal NK Cell Lymphoma

Sponsor

M.D. Anderson Cancer Center

Enrollment

40 participants

Start Date

Jan 16, 2015

Study Type

INTERVENTIONAL

Conditions

Lymphoma

Summary

The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination of these therapies given at the same time is investigational. Up to 40 patients will take part in this study. All will be enrolled at MD Anderson.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a combination of chemotherapy and radiation therapy delivered at the same time for patients newly diagnosed with early-stage nasal NK cell lymphoma, a rare type of cancer that starts in the lining of the nose and sinuses. **You may be eligible if...** - You have been newly diagnosed with stage I or II nasal NK cell lymphoma - Your blood counts, liver, and kidney function are at acceptable levels - Your heart is pumping blood effectively (ejection fraction at least 50%) - You are willing and able to use contraception during the study - You are not pregnant (a negative pregnancy test is required for women) **You may NOT be eligible if...** - You have an active Hepatitis B or C infection - You have significant heart problems - You cannot meet the blood count or organ function requirements - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONRadiation Therapy

Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.

DRUGDexamethasone

40 mg by vein Days 1-3 in a 21 day cycle.

DRUGEtoposide phosphate

67 mg/m2 by vein on Days 1-3 of a 21 day cycle.

DRUGIfosfamide

1 g/m2 by vein on Days 1-3 of a 21 day cycle.

DRUGMesna

0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.

DRUGCarboplatin

200 mg/m2 by vein on Day 1 of a 21 day cycle.

Locations(1)

MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02106988

Related Trials

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

NCT073023477 locations

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

NCT054031773 locations

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT052379863 locations

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

NCT0701524240 locations

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

NCT058918211 location